Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour which arises from thyroid C-cells. It accounts for 5 to 10% of all thyroid cancers. Total thyroidectomy with lymph node dissection is the main treatment when the disease is confined to the neck (Chi and Moley, 1998; Schlumberger and Pacini, 1999). External irradiation to the neck may be indicated in the absence of known distant disease, in patients with a detectable CT level after an apparently complete surgical procedure, and in those with an inoperable disease (Tubiana et al, 1985; Brierley et al, 1996; Fife et al, 1996). This procedure reduces the recurrence rate in the neck, but its impact on patients’ survival has still to be demonstrated. Chemotherapy plays no role in the early management (Chi and Moley, 1998; Schlumberger and Pacini, 1999).

This disease usually follows an indolent course even at the stage of distant spread, and patients with lung or liver metastases may survive years without systemic treatment (Saad et al, 1984; Tubiana et al, 1985; Van Heerden et al, 1990; Chi and Moley, 1998; Brierley et al, 1996). In a minority of these metastatic patients, chemotherapy may be indicated for rapidly progressive distant metastases (Cailleux and Schlumberger, 1998).

Chemotherapy trials have been limited by the scarcity of these tumours. Furthermore, due to the indolent course of the disease and the poor results of chemotherapy, only patients with large tumour burden or rapidly progressing distant metastases have been included in these trials. Response rates were low with doxorubicin (Shimaoka et al, 1985; Droz et al, 1990) and cisplatin (Hoskin and Harmer 1987; Droz et al, 1990), given either as single agents or in combination (Shimaoka et al, 1985; Williams et al, 1986; De Besi et al, 1991). Furthermore, toxicities were significant.

A trial (Schlumberger et al, 1995) with etoposide given as a single agent did not confirm a previous report (Hoskin and Harmer, 1987) as no tumour response was observed among 16 evaluable patients.

Combination of drugs which have been shown to be active in the treatment of other neuroendocrine tumours may provide further therapeutic options in MTC patients. Indeed, several trials carried out on limited numbers of MTC patients have shown that these drugs are active in some. With the combination of 5-FU-dacarbazine, a complete response was observed in one patient (Pertusson, 1988), and 3 partial responses were observed among 5 patients (Orlandi et al, 1994). Two partial responses were observed among 7 patients treated with cyclophosphamide, vincristine and dacarbazine (Wu et al, 1994). With a combination of doxorubicin and streptozocin, one partial response was obtained among 5 patients (Frame et al, 1988), and using a combination of epirubicin, 5-FU and dacarbazine, one partial response was observed among 7 patients (Di Bartolomeo et al, 1995). In a previous study (Schlumberger et al, 1995), combinations of 5-FU/streptozocin and 5-FU/dacarbazine were given alternatively to 20 patients. Three partial responses and 11 stabilizations were observed.

Considering these results, the alternating combinations of doxorubicin/streptozocin and 5-FU/dacarbazine, that have already been used in gastro-entero-pancreatic neuroendocrine tumours (Moertel et al, 1994), were given to 20 patients with progressive metastatic MTC.

**PATIENTS AND METHODS**

**Patients**

From October 1994 to February 1999, 20 patients (Table 1) with progressive distant metastases of MTC were entered into this trial. Their mean age was 49 years (range 30–79). There were 14 males and 6 females. Among them, 16 had undergone a total thyroidectomy with bilateral cervical lymph node dissection, and 10 had...
received post-operatively external radiotherapy to the neck and mediastinum. Four patients were not operated on for diffuse distant metastases at presentation or locally advanced disease. None of them had previously been treated with chemotherapy. Median follow-up since the diagnosis was 4.5 years (range, 2.3–37 years).

All patients had measurable metastatic lesions that were documented by chest radiography, neck or liver ultrasonography, and neck, chest or abdominal CT scan or magnetic resonance imaging. These lesions have progressed during the preceding 3–6 months. The tumour markers calcitonin (CT) and carcinoembryonic antigen (CEA) were measured and followed in all patients but were not accepted as the only response criteria.

Other eligibility requirements were as follows: ECOG status <2, no major ECG changes and an ejection fraction >50% as measured by an isotopic technique; leucocyte count greater than 4 000 µl–1 and platelet count greater than 150 000 µl–1, a serum creatinine of 120 µmol l–1 or less, a 24 h proteinuria <200 mg, a total bilirubin of less than or equal to 34 µmol l–1.

All patients were evaluated upon entry into the study, and after every 2 courses of chemotherapy, with clinical staging, CT and CEA measurements and morphological investigations including chest X-ray, neck and liver ultrasonography and chest or abdominal CT scan. Routine chemistry and ECG were performed before each course of chemotherapy.

The study was approved by the local Ethics Committee and an informed consent was obtained from all patients.

### Treatment

The chemotherapy protocol consisted in doxorubicin 60 mg/m² i.v. in 5 minutes on day 1, and streptozocin 300 mg/m² in 4 hours perfusion, daily for 5 consecutive days. Four weeks later, 5-FU was given at 400 mg/m², and dacarbazine at 200 mg/m², both by intravenous injection daily for 5 consecutive days. At 8 weeks, this cycle was repeated.

Three categories of response were assessed: (1) tumour, (2) biochemical, and (3) symptomatic. The criteria used for reporting responses for measurable tumour masses were those of Miller et al (1981): partial remission (PR) was defined as greater than or equal to 50% decrease in the sum of the products of the two largest perpendicular diameters of all tumour masses for at least 1 month; no change (NC), defined as less than 50% decrease or less than 25% increase in the size of measurable lesions; progressive...
disease (P) defined as greater than or equal to 25% increase in any tumour lesion or the appearance of new site. For biochemical response, PR was defined as greater than or equal to 50% decrease for at least 1 month. For symptomatic response, PR was defined as a reduction of at least 50% in both the frequency and intensity of flushing and/or diarrhoea attacks. In those patients who achieved a partial response, the period of overall duration of response was calculated from the first day of treatment to the date of first observation of progressive disease.

Toxicity was evaluated monthly and complete re-staging was performed after 2, 4 and 6 cycles of chemotherapy. Therapy was continued until tumour progression, and in cases of tumour response or stabilization for a total of 6 cycles (12 months), and as long as there was no evidence of symptomatic or general deterioration or toxicity.

RESULTS

The 20 patients entered into this trial were evaluable for toxicity and response. Each patient received an average of 4 (range 2 to 6) cycles of doxorubicin-streptozocin and 5-FU-dacarbazine.

Four of the 5 patients with invalidating symptoms before starting chemotherapy had a partial symptomatic response.

Three partial tumour responses were obtained after 3, 2 and 3 cycles of chemotherapy, and lasted 27, 28+ and 18 months, respectively. Calcitonin level decreased by 65%, 73% and 58% respectively, and CEA level was stable in one patient, was normal in one before therapy, and decreased by 60% in one.

Ten patients had a stable disease for 8–51 months (mean 23 months). Among these 10 patients, 3 had progressive marker levels, 4 had stable marker levels and 3 had a partial biological response. Seven patients had progressive disease.

Nausea and vomiting were limited by antiemetic drugs and digestive toxicity was observed in 5 patients (grade 2 in 3 and grade 3 in 2). One patient had a grade 2 stomatitis. Hepatic toxicity (grade 2) was observed in one patient, haematologic toxicity in 2 patients (grade 3 and 4), and cardiac toxicity in two patients (grade 3). There were no treatment-related deaths.

With a mean follow-up of 25 months (range, 8–60 months) since the beginning of therapy, seven deaths occurred, including one of the 3 patients who had responded to therapy, 2 among the 10 patients who achieved a stabilisation of the disease, and 4 in the 7 patients with progressive disease.

DISCUSSION

The alternating combination of doxorubicin-streptozocin, and 5-FU-dacarbazine, was used because it combines drugs that have been shown to be active in medullary thyroid carcinoma, when used separately; also, this association has been shown to be active in other neuroendocrine tumors, with an acceptable toxicity (Moertel et al, 1994).

In 20 patients with metastatic MTC, it resulted in 3 partial responses (15%), and in 10 long-term stabilisations (50%). Considering that all patients included in the trial were affected by a rapidly progressing disease, these results confirm the potential benefits of cytotoxic chemotherapy, and are in agreement with the results obtained with the association of epirubicin, dacarbazine and 5-FU (Di Bartolomeo et al, 1995).

Nevertheless, the response rate was not improved by adding doxorubicin to the previously tested regimen of streptozocin plus 5-FU and dacarbazine, and toxicity was slightly higher (Schlumberger et al, 1995). Therefore, we consider the previous regimen as the reference combination for metastatic MTC patients with rapidly progressing disease. The absence of synergistic effect among these cytotoxic agents can be attributed to the large size of the neoplastic masses and also to intrinsic cellular factors determining chemoresistance (Yang et al, 1991).

Nevertheless, because of the high metastatic potential of medullary thyroid carcinoma, further studies are necessary in order to identify new therapeutic strategies with cytotoxic or cytostatic molecules that will permit the treatment of these patients at an earlier stage.

REFERENCES

Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S and Panzarella T (1996) Medullary thyroid cancer: analysis of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6: 305–310
Cailloux AF and Schlumberger MJ (1998) Chemotherapy and biological therapy of thyroid cancer. In: Thyroid cancer J Fain (ed), Kluwer Academic Publishers, Boston, pp 341–350
Chi DD and Moley JF (1998) Medullary thyroid carcinoma: genetic advances, treatment recommendation and the approach to the patient with persistent hypercalcitoninemia. Surg Oncol Clin N Am 7: 681–706
De Berti P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat P and Fiorentino MV (1991) Combined chemotherapy with bleomycin, adriamycin and platinum in advanced thyroid cancer. J Endocrinol Invest 14: 475–480
Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferrro V, Visini M, Gebbia V, Tumolo S and Ballatore P (1995) A phase II trial of dacarbazine, fluorouracil and epirubicin in patient with neuroendocrine tumors. A study by the italian trials in medical oncology (ITMO) group. Ann Oncol 6: 77–79
Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P and Parmentier C (1990) Chemotherapy in metastatic non anaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76: 480–483
Fife KM, Bower M and Harmer CL (1996) Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol 22: 588–591
Frame J, Kelsen D, Kemeny N, Cheng E, Niedzwiecki D, Heelan R and Lipperman RA (1988) A phase II trial of streptozocin and adriamycin in advanced APUD tumors. Ann J Clin Oncol 11: 490–495
Hoskin PJ and Harmer C (1987) Chemotherapy for thyroid cancer. Radiother Oncol 10: 187–194
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Moertel CG, Johnson CM, McKusick JK Jr, Nagorney DM, Kools LK, Rubin J and Kunselman S (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120: 302–309
Orlandi F, Caraci P, Berruti A, Paligheddu B, Pivano G, Dogliotti L and Angelini A (1994) Chemotherapy with dacarbazine and 5-fluoro-uracil in advanced medullary thyroid cancer. Ann Oncol 5: 763–765
Petrusson SR (1988) Metastatic medullary thyroid carcinoma: complete response to combination chemotherapy with dacarbazine and 5-fluoro-uracil. Cancer 62: 1899–1903
Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS, Hickey RC and Saaman NA (1984) Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63: 319–342
Schlumberger M and Pacini F (1999) Medullary thyroid carcinoma. In: Thyroid tumors. Editions Nucloen, Paris, pp 267–299
Schlumberger M, Abdelmonemene N, Delisle MI and Coutte JE (1995) Treatment of advanced medullary thyroid cancer with an alternating combination of 5-FU-streptozocin and 5 FU-dacarbazine. Br J Cancer 71: 363–365 365.
Shimaoka K, Schoenfeld DA, De Wys WD, Creech RH and De Conti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56: 2155–2160
Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P and Sarrazin D (1985) External radiotherapy in thyroid cancers. Cancer 55: 2062–2071
Van Heerden JA, Grant CS, Gharib H, Hay ID and Illstrup DM (1990) Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212: 395–401
Williams SD, Birch R and Einhorn LH (1986) Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a southeastern cancer study group trial. Cancer Treat Rep 70: 405–407
Wu LT, Averbuch SD, Ball DW, De Bustros A, Baylin SB and Mac Guire III WP (1994) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine and dacarbazine. Cancer 73: 432–436
Yang KP, Liang YF and Samaan NA (1991) Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdrl gene and low proliferation fraction. Anticancer Res 11: 1065–1068